Clinical trials: Benign Meningioma
High Risk Meningioma, Recurrent Meningioma
68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma
The is phase 1 trial of 68Ga-Dotatate PET/MRI guided radiation dose escalation for high-risk meningiomas (defined as recurrent or subtotal resection of Grade 2, and any Grade 3 meningioma).
- Trial name
- NCT07353229
- Testing
- ⁶⁸Ga-Dotatate PET and MRI Guided Radiation Therapy, Magnetic Resonance Imaging (MRI), 68Ga-Dotatate PET Imaging
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Thomas Jefferson University
Iodine-resistant Thyroid Cancer, Meningioma
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
The US FDA approved a targeted somatostatin receptor 2 imaging agent, 68Ga-DOTATATE, in 2016. It has higher uptake in small cell lung cancer, pulmonary carcinoid, and medullary thyroid cancer.
- Conditions
- Iodine-resistant Thyroid Cancer, Meningioma, NETs
- Trial name
- NCT06632860
- Testing
- 68Ga-TATE-RGD, 18-FDG
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Brain Tumor, Brain Metastases
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in patients with Advanced Brain Cancer including Gliomas and…
- Conditions
- Brain Tumor, Brain Metastases, Brain Cancer, Glioma
- Trial name
- BAH2472 (NCT06640582)
- Testing
- Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Tumor, Brain, Meningioma of Brain
Intraoperative Brain Shift Calculation Study
The purpose of the study is to calculate magnitude, type of intraoperative brain shift and assess possibility of it's prediction.
- Conditions
- Tumor, Brain, Meningioma of Brain, Glioma, Metastasis Brain
- Trial name
- BRASH (NCT05477680)
- Testing
- Navigation-guided surgery
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Sklifosovsky Institute of Emergency Care
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Brain Tumor, Recurrent, Brain Tumor
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
- Conditions
- Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic
- Trial name
- NCT04427384
- Testing
- GammaTile
- Where
- 54 sites in United States
- Volunteers
- 600 people
- Sponsor
- GT Medical Technologies, Inc.
Meningioma
Magnesium and Intraoperative Blood Loss in Meningioma Surgery
Meningioma is the most common central nervous system tumor and craniotomy with tumor removal was associated with moderate blood loss and blood transfusion.
- Trial name
- NCT03558516
- Testing
- Magnesium group, Normal saline group
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Mahidol University
Quality of Life, Meningioma
Translation and Validation of the MQOL Self-questionnaire Into French for Assessing Quality of Life in Patients With Meningiomas
Meningiomas, which account for about 40% of primary central nervous system tumors, have significant psychological and social impacts, even without treatment.
- Trial name
- MenQOL (NCT07044076)
- Testing
- Quality of life
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier St Anne
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00020150
- Testing
- O6-benzylguanine, temozolomide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Low-grade Glioma, Meningioma
FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery
In neurosurgery both the diffusely infiltrated gliomas of the brain as well as the border towards healthy tissue in the meninges is a challenge.
- Conditions
- Low-grade Glioma, Meningioma, Glioma
- Trial name
- NCT06684795
- Testing
- FG001 prior to surgery
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Meningioma
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
- Trial name
- STELLAR-201 (NCT07428616)
- Testing
- Zanzalintinib
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Exelixis
Meningioma, Radiation Toxicity
Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:
For the purpose of this research, investigator will constitute several cohorts of patients, treated either by intensity-modulated radiotherapy, stereotactic radiotherapy or proton-therapy.
- Trial name
- CANCER-COG (NCT06036706)
- Testing
- Normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning, Hypo-fractionated stereotactic brain irradiation, Normo-fractionated proton therapy brain irradiation
- Where
- 3 sites in France
- Volunteers
- 108 people
- Sponsor
- Centre Francois Baclesse
Unruptured Intracranial Aneurysms, Pituitary Neuroendocrine Tumor
China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm
The goal of this observational study is to learn about the treatment strategies for tumor in sellar region with unruptured intracranial aneurysms in the Chinese population.
- Conditions
- Unruptured Intracranial Aneurysms, Pituitary Neuroendocrine Tumor, Craniopharyngioma, Meningioma
- Trial name
- ChTTSRUIA (NCT07809178)
- Testing
- Tumor resection followed by aneurysm treatment, Aneurysm treatment followed by tumor resection, Observation
- Where
- China
- Volunteers
- 608 people
- Sponsor
- Cheng sen
Cancer, Breast Cancer
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the…
- Conditions
- Cancer, Breast Cancer, Lung Cancer, Colon Cancer
- Trial name
- LIBERATE (NCT03702309)
- Where
- Canada
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Brain and Central Nervous System Tumors, Cognitive/Functional Effects
Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain
RATIONALE: Donepezil may decrease the side effects caused by radiation therapy to the brain. PURPOSE: This clinical trial is studying how well donepezil works in treating young patients with primary brain tumors previously…
- Conditions
- Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity
- Trial name
- NCT00452868
- Testing
- Donepezil
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences
Neuroblastoma, Medulloblastoma
Molecular-Guided Therapy for Childhood Cancer
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup.
- Conditions
- Neuroblastoma, Medulloblastoma, Glioma, Ependymoma
- Trial name
- NCT02162732
- Testing
- Guided Therapy
- Where
- 19 sites in United States, Lebanon
- Volunteers
- 186 people
- Sponsor
- Giselle Sholler
Meningioma Atypical
Identification by Transcriptomic Approach of New Prognostic and Predictive Markers in a Cohort of Atypical Meningiomas
Determine by a transcriptomic approach new prognostic and predictive markers in atypical meningiomas (WHO grade II). Retrospective observational study, on a cohort of 85 atypical meningiomas.
- Trial name
- TransMenAtyp (NCT05259332)
- Where
- France
- Volunteers
- 85 people
- Sponsor
- Central Hospital, Nancy, France
Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
This phase I trial is studying the side effects and best dose of vorinostat when given together with bortezomib in treating young patients with refractory or recurrent solid tumors, including CNS tumors and lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT00994500
- Testing
- vorinostat, bortezomib, pharmacological study
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma
- Trial name
- NCT00112619
- Testing
- topotecan hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pediatric Brain Tumor Consortium